FierceBiotechOriginal article
{"a":[{"_":"Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 win","$":{"href":"/biotech/roivants-14m-bet-bayers-inhaled-hypertension-med-pays-phase-2-win","hreflang":"en"}}]}
Phase 2positivePositive
AI Analysis
Summary
Roivant's $14 million investment in Bayer's inhaled pulmonary hypertension drug has yielded positive phase 2 study results. The drug successfully met its study endpoints in the lung disease trial.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
Inhaled hypertension medication met phase 2 study endpoints
Importance:7/10
Sentiment:
0.75
phase 2 datapulmonary hypertensioninhaled medicationpartnership
Related Companies
Read the original article
Published by FierceBiotech on September 6, 2026 4:12 AM